Shanghai Bio-heart Biological Technology Co., Ltd. (02185.HK) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 19Aug 24Aug 28Sep 2Sep 7Sep 10Sep 15Sep 18

Key dataSep 18, 2026

OpenHKD 1.61

From 52W high−83.76%

Volume185100.00

Market capHKD 357.82M

P/E (TTM)—

P/S (TTM)8.1x

Div yield—

Key dataSep 18, 2026

Open

HKD 1.61

From 52W high

−83.76%

Volume

185100.00

Market cap

HKD 357.82M

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−3.9x

P/E (TTM)

—

RSI (14)

31.0

MomentumView details →

1D Return

−8.13%

YTD Return

−74.61%

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−3.9x

EV/Sales

6.8x

P/S (TTM)

8.1x

P/B (TTM)

0.8x

ProfitabilityView details →

Gross Margin

−2.29%

Net Margin

−196.41%

EBITDA Margin

−175.11%

ROE (TTM)

−18.49%

ROA (TTM)

−9.40%

Asset Turnover

0.05x

GrowthView details →

Revenue YoY

+81.42%

EPS YoY

+16.62%

FCF YoY

+29.66%

Revenue CAGR 3Y

—

EPS CAGR 3Y

+22.22%

EBITDA YoY

−50.02%

MomentumView details →

1D Return

−8.13%

YTD Return

−74.61%

1Y Return

−79.72%

RSI (14)

31.0

vs 50D SMA

−32.02%

vs 200D SMA

−63.41%

Capital & dividendView details →

Debt/Equity

0.03x

Current Ratio

23.75x

Quick Ratio

21.50x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−HKD 0.15

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

—

Avg Surprise (4Q)

—

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

58.71M

Net Income (TTM)

−163.66M

Op. CF (TTM)

−126.79M

Next earningsMar 26, 2027 →

Latest newsMore news →

Shanghai Bio-Heart Biological Technology entered into a strategic cooperation agreement with Shenqi Medical to jointly advance the commercialization and clinical application of the Bioheart® bioresorbable rapamycin-eluting coronary stent system.6d ago

Bioheart Inc. (02185) announced that it recently entered into a strategic cooperation agreement with Shanghai Shenqi Medical to jointly advance the commercialization and clinical application of its independently developed Bioheart bioresorbable rapamycin-eluting coronary stent system (BioHeart stent).6d ago

Similar companies

Sirnaomics Ltd.02257.HK Ocugen, Inc.OCGN Enanta Pharmaceuticals, Inc.ENTA X4 Pharmaceuticals, Inc.XFOR Agenus Inc.AGEN Alpha Tau Medical Ltd.DRTSW Find similar companies →

Latest newsMore news →

Shanghai Bio-Heart Biological Technology entered into a strategic cooperation agreement with Shenqi Medical to jointly advance the commercialization and clinical application of the Bioheart® bioresorbable rapamycin-eluting coronary stent system.6d ago Bioheart Inc. (02185) announced that it recently entered into a strategic cooperation agreement with Shanghai Shenqi Medical to jointly advance the commercialization and clinical application of its independently developed Bioheart bioresorbable rapamycin-eluting coronary stent system (BioHeart stent).6d ago